Stem Cell Therapeutics Corp.: Traumatic Brain Injury (TBI) Clinical Study Gains IRB Approval at University of Calgary

   Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the "Company") wishes to announce the IRB (Institutional Review Board) at the University of Calgary/Foothills Hospital has approved the SCT-sponsored investigator-lead Phase IIa study entitled "A Phase IIa, Single Center, Open Label Study to Characterize the Safety of Human Chorionic Gonadotrophin (hCG) and Epoeitin Alpha (EPO) in Traumatic Brain Injury".

The study which was approved and which would be, lead by Dr David Zygun, of the University of Calgary, is a single center open label study to characterize the safety of hCG and EPO in traumatic brain injury patients ("TBI"). A series of efficacy endpoints are part of the trial design in order to access various aspects of neurological status. Dr Alan Moore, President and CEO of SCT said "We are excited to see this study reach final approval stage, which is a significant milestone, and look forward to determine the effects of the hCG+EPO regimen in patients with TBI. However, as stated in our June 25, 2010 press release, the Company continues to move forward as a biotech company considering a range of options. Management continues to focus its efforts on pursuing the end-of-Phase II meeting with the FDA for the NTx®-265 stroke therapy while concurrently reviewing alternatives for pursuing the traumatic brain injury ("TBI") and multiple sclerosis ("MS") study opportunities."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President and CEO 403-245-5495 ext.224 [e-mail] Stem Cell Therapeutics Corp. Angelika Goncalves DaSilva Operations Manager 403-245-5495 ext. 221 [e-mail] www.stemcellthera.com